
Merck’s novel insomnia drug suvorexant has improved patients’ ability to fall asleep, according to new data from two Phase III …
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals

